Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Новые векторы в диагностике метаболического синдрома: оценка уровня сосудистого эндотелиального фактора роста, пентраксина-3 и трансформирующего фактора роста бета

https://doi.org/10.15829/1728-8800-2019-6-57-61

Полный текст:

Аннотация

В статье представлены результаты отечественных и зарубежных клинических исследований, посвященных изучению уровня маркеров ангиогенеза — сосудистый эндотелиальный фактор роста, пентраксин-3 и трансформирующий фактор роста бета, у пациентов с метаболическим синдромом.

Об авторах

Р. Н. Шепель
Национальный медицинский исследовательский центр профилактической медицины Минздрава России
Россия

Шепель Руслан Николаевич - научный сотрудник отдела фундаментальных и прикладных аспектов ожирения, начальник отдела организационно-методического управления и анализа качества медицинской помощи.

Москва.

Тел.: +7 (915) 078-77-54



О. М. Драпкина
Национальный медицинский исследовательский центр профилактической медицины Минздрава России
Россия

Драпкина Оксана Михайловна - доктор медицинских наук, профессор, член-корреспондент РАН, директор.

Москва.



Список литературы

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation. 2009;120(16):1640-5. doi:10.1161/CIRCULATIONAHA.109.192644.

2. Alberti KG, Zimmet P. The metabolic syndrome — a new worldwide definition. The Lancet. 2005; 366(9491 ):1059-62. doi:10.1016/S0140-6736(05)67402-8.

3. Мычка В. Б., Жернакова Ю.В., Чазова И. Е. Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома. Второй пересмотр. Практическая медицина. 2010;3(54):15-8.

4. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi:10.1155/2014/943162.

5. Delavari A, Forouzanfar MH, Alikhani S, et al. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care. 2009; 32(6):1092-7 doi:10.2337/dc08-1800.

6. Metelskaya VA, Shkolnikova MA, Shalnova SA, et al. Prevalence, components, and correlates of metabolic syndrome (MetS) among elderly Muscovites. Arch Gerontol Geriatr. 2012;55(2):231-7 doi:10.1016/j.archger.2011.09.005.

7. Шавшин Д. А., Ротарь О. П., Солнцев В. Н. и др. Распространенность метаболического синдрома в выборке жителей Калининграда. Артериальная гипертензия. 2015;21(6):630-8. doi:10.18705/1607-419X-2015-21-6-630-638.

8. Воевода М. И., Ковалькова Н. А., Рагино Ю. И. и др. Распространенность метаболического синдрома у жителей Новосибирска в возрасте от 25 до 45 лет. 30. Терапевтический архив. 2016;88(10):51-6. doi:10.17116/terarkh2016881051-56.

9. Wilson PWF, Kannel WB, Silbershatz H, DAgostino RB. Clustering of metabolic factors and coronary heart disease. Archives of Internal Medicine. 1999;159(10):1104-9. doi:10.1001/archinte.159.10.1104.

10. Palaniappan L, Carnethon MR, Wang Y, et al. Predictors of the incident metabolic syndrome in adults: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27(3):788-93. doi:10.2337/diacare.27.3.788.

11. Srikanthan K, Feyh A, Visweshwar H, et al. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci. 2016;13(1):25-38. doi:10.7150/ijms.13800.

12. Soares R, Costa C. Oxidative stress, inflammation and angiogenesis in the metabolic syndrome. Springer. Heidelberg, Germany, 2009. ISBN: 978-1-4020-9701-0. doi:10.1007/978-1-4020-9701-0.

13. Miyazono K, Usuki K, Heldin CH. Platelet-derived endothelial cell growth factor. Prog Growth Factor Res. 1991;3:207-17.

14. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-8. doi:10.1038/35025215.

15. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-78. doi:10.1016/j.cytogfr.2005г.01.004.

16. Ohnishi T, Daikuhara Y. Hepatocyte growth facto r/scatter factor in development, inflammation and carcinogenesis: its expression and role in oral tissues. Arch Oral Biol. 2003;48:797-804. doi:10.1016/s0003-9969(03)00180-8.

17. Zafar MI, Mills K, Ye X, et al. Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis. Diabetol Metab Syndr. 2018;10:62. doi: 10.1186/s13098-018-0363-0.

18. Elias I, Franckhauser S, Ferre T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes. 2012;61:1801-13. doi:10.2337/db11-0832.

19. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia. 2003;46:1483-8. doi:10.1007/s00125-003-1221-6.

20. Garcia de la Torre N, Rubio MA, BordiC E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008;93:4276-81. doi:10.1210/jc.2007-1370.

21. Gomez-Ambrosi J, Catalan V, Rodriguez A, et al. Involvement of serum vascular endothelial growth factor family members in the development of obesity in mice and humans. J Nutr Biochem. 2010;21:774-80. doi:10.1016/j.jnutbio.2009.05.004.

22. Tinahones FJ, Coin-Araguez L, Mayas MD, et al. Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels. BMC Physiol. 2012;12:4. doi:10.1186/1472-6793-12-4.

23. Robciuc MR, Kivela R, Williams IM, et al. VEGFB/VEGFR1-induced expansion of adipose vasculature counteracts obesity and related metabolic complications. Cell Metab. 2016;23:712-24. doi:10.1016/j.cmet.2016.03.004.

24. Lijnen HR, Christiaens V, Scroyen I, et al. Impaired adipose tissue development in mice with inactivation of placental growth factor function. Diabetes. 2006;55:2698-704. doi:10.2337/db06-0526.

25. Pervanidou P, Chouliaras G, Akalestos A, et al. Increased placental growth factor (PlGF) concentrations in children and adolescents with obesity and the metabolic syndrome. Hormones (Athens). 2014;13(3):369-73. doi:10.14310/horm.2002.1491.

26. Siervo M, Ruggiero D, Sorice R, et al. Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. J Intern Med. 2010;268:338-47. doi:10.1111/j.1365-2796.2010.02255.x.

27. Siervo M, Ruggiero D, Sorice R, et al. Body mass index is directly associated with biomarkers of angiogenesis and inflammation in children and adolescents. Nutrition. 2012;28:262-6. doi:10.1016/j.nut.2011.06.007.

28. Wada H, Satoh N, Kitaoka S, et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis. 2010;208:512-7. doi:10.1016/j.atherosclerosis.2009.07.045.

29. Petrovic D, Verhovec R, Globocnik Petrovic M, et al. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology. 2007;107:291-5. doi:10.1159/000099064.

30. Lin TH, Wang CL, Su HM, et al. Functional vascular endothelial growth factor gene polymorphisms and diabetes: Effect on coronary collaterals in patients with significant coronary artery disease. Clin Chim Acta. 2010;411:1688-93. doi:10.1016/j.cca.2010.07.002.

31. Kim YR, Hong SH. Association between the polymorphisms of the vascular endothelial growth factor gene and metabolic syndrome. Biomed Rep. 2015;3(3):319-26. doi:10.3892/br.2015.423.

32. Karakas MF, Buyukkaya E, Kurt M, et al. Serum pentraxin-3 levels are associated with the severity of metabolic syndrome. Med Princ Pract. 2013;22(3):274-9. doi:10.1159/000343904.

33. Zanetti M, Bosutti A, Ferreira C, et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med. 2009;9(3):243-8. doi:10.1007/s10238-009-0039-z.

34. Kardas F, Akin L, Kurtoglu S, et al. Plasma Pentraxin 3 as a biomarker of metabolic syndrome. Indian J Pediatr. 2015;82(1):35-8. doi:10.1007/s12098-014-1542-0.

35. Gurel H, Genc H, Celebi G, et al. Plasma pentraxin-3 is associated with endothelial dysfunction in non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2016;20(20):4305-12.

36. Ozturk K, Kurt O, Dogan T, et al. Pentraxin 3 Is a Predictor for Fibrosis and Arterial Stiffness in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract. 2016;2016:1417962. doi:10.1155/2016/1417962.

37. Lee R, Ahn HR, Shin MH, et al. Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study. J Atheroscler Thromb. 2019 Jan 23 [Epub ahead of print]. doi:10.5551/jat.47167.

38. Miyazaki T, Chiuve S, Sacks FM, et al. Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. PLoS One. 2014;9(4):e94073. doi:10.1371/journal.pone.0094073.

39. Castaneda A, Jauregui-Maldonado E, Ratnani I, et al. Correlation between metabolic syndrome and sleep apnea. World J Diabetes. 2018;9(4):66-71. doi:10.4239/wjd.v9.i4.66.

40. Nabrdalik К, Chodkowski А, Bartman W, et al. Pentraxin 3 and atherosclerosis among type 2 diabetic patients. Open Life Sciences. 2016;12(1):92-8. doi:10.1016/j.diabres.2012.11.020.

41. Lin E, Kuo PH, Liu YL, et al. Transforming growth factor-в signaling pathway-associated genes SMAD2 and TGFBR2 are implicated in metabolic syndrome in a Taiwanese population. Scientific Reports 2017;7:13589. doi:10.1038/s41598-017-14025-4.

42. Yadav H, Quijano C, Kamaraju AK, et al. Protection from obesity and diabetes by blockade of TGF-p/Smad3 signaling. Cell Metab. 2011;14(1):67-79. doi:10.1016/j.cmet.2011.04.013.

43. Mendes NF, Gaspar JM, Lima-JCnior JC, et al. TGF-P1 down-regulation in the mediobasal hypothalamus attenuates hypothalamic inflammation and protects against diet-induced obesity. Metabolism. 2018;85:171-82. doi:10.1016/j.metabol.2018.04.005.

44. Rosmond R, Chagnon M, Bouchard C, et al. Increased abdominal obesity, insulin and glucose levels in nondiabetic subjects with a T29C polymorphism of the transforming growth factor-Pgene. Hormone Research. 2003;59(4): 191-4. doi:10.1159/000069323.

45. Samad F, Yamamoto К, Pandey М, et al. Elevated expression of transforming growth factor-в in adipose tissue from obese mice. Molecular Medicine. 1997;3(1):37-48.

46. Raju J, Bajaj G, Chrusch J, et al. Obese state leads to elevated levels of TGF-в and COX isoforms in platelets of Zucker rats. Molecular and Cellular Biochemistry. 2006;284(1-2):19-24. doi:10.1007/s11010-005-9008-3.

47. Sciarretta S, Ferrucci A, Ciavarella GM, et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens. 2007;20(7):784-91. doi:10.1016/j.amjhyper.2007.01.023.

48. Herder С, Zierer А, Koenig W, et al. Transforming growth factor^ and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care. 2009;32(10):1921-3. doi:10.2337/dc09-0476.


Для цитирования:


Шепель Р.Н., Драпкина О.М. Новые векторы в диагностике метаболического синдрома: оценка уровня сосудистого эндотелиального фактора роста, пентраксина-3 и трансформирующего фактора роста бета. Кардиоваскулярная терапия и профилактика. 2019;18(6):57-61. https://doi.org/10.15829/1728-8800-2019-6-57-61

For citation:


Shepel R.N., Drapkina O.M. New directions in metabolic syndrome diagnosis: assessment of vascular endothelial growth factor, pentraxin-3 and transforming growth factor beta levels. Cardiovascular Therapy and Prevention. 2019;18(6):57-61. (In Russ.) https://doi.org/10.15829/1728-8800-2019-6-57-61

Просмотров: 45


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)